Capstone Holding Corp. — Director's Dealing 2017

Jul 24, 2017

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Capstone Therapeutics Corp. (CAPS)
CIK: 0000887151
Period of Report: 2017-07-14

Reporting Person: Lipman Matthew E. (Director, 10% Owner)
Reporting Person: BP Peptides, LLC (10% Owner)

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock, $0.0005 par value	18541197	Indirect

Footnotes

F1: This Form 3 is filed jointly by BP Peptides, LLC ("BP Peptides") and Matthew E. Lipman (collectively, the "Reporting Persons"). Mr. Lipman is a director of the Issuer. BP Peptides may be deemed to be a director by deputization by virtue of the fact that Mr. Lipman, the Manager and President of BP Peptides, is a director of the Issuer.

F2: Represents securities owned directly by BP Peptides. As the Manager and President of BP Peptides, Mr. Lipman may be deemed to beneficially own the securities owned directly by BP Peptides. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein.